Improving outcomes with anti-BCMA bispecific antibodies with attention to infection - Takeaways - MDSpire

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection

  • By

  • Andrew J. Yee

  • July 8, 2024

  • 0 min

Share

  • 1

    Anti-BCMA therapies are revolutionizing multiple myeloma treatment, offering significant response rates in heavily treated patients.

  • 2

    Infection risks are heightened with anti-BCMA bispecific antibodies, with severe infections occurring in 40% of patients compared to 26% with CAR T-cells.

  • 3

    Hypogammaglobulinemia is common with anti-BCMA therapies, impacting infection rates, particularly with bispecific antibodies.

  • 4

    Intravenous immunoglobulin prophylaxis significantly reduces serious infection rates in patients with hypogammaglobulinemia.

  • 5

    Adjusting dosing intervals for bispecific antibodies can lower infection rates, with FDA approval for biweekly dosing in certain patient scenarios.

Original Source(s)

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection

  • by Andrew J. Yee

  • July 8, 2024

Related Content

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

Rare COVID Vaccine Clotting Linked to Adenoviral Protein 

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies 

  • April 21, 2026

  • 2 min